I too after quite some time deliberating for or against will be voting in favour with 100% positively to support our new board and company , agree there has been some mistakes and things that could have been executed better and faster around the world , , but the world has changed significantly also , the approval processes around the world has changed and also here in Australia, ADO the small company has changed and grown significantly for the better , its a different company from 12 months ago , there has been changes made giving a massive transformation priming the company for success .
Think carefully, you can change your vote and your mind, a vote against now in my opinion will only hurt the company we all love and has given us the second highest ASX listed market cap appreciating company in the last 12 months., I strongly believe the same capital appreciation will happen in the next 12 months with a quick read below.
Three industry experienced executives join AnteoTech
o Mr Ian Steinhardt - Head of Market Operations –
Life Sciences o Mr Pierre Nathie - Head of Products & Services – Life Sciences
o Mr Tim Pritchard - CFO and Company Secretary
The strengthened management team is well-positioned to drive and deliver the Company’s growth strategy.
AnteoTech positions Board for growth and establishes Advisory Boards Highlights
❖ Appointment of Ms Glenda McLoughlin and Dr Katherine Woodthorpe AO as non-executive directors
❖ AnteoTech establishes Advisory Boards to support the Life Sciences and Energy businesses
❖ Energy Advisory Board to be founded by Mr. Oliver Gross and Dr Kevin Eberman
❖ Clinical Advisory Board to be founded by Prof. Paul Young and Prof. Dominic Dwyer
Building a Global Market Distribution Network AnteoTech’s go-to market strategy for EuGeni is based on a distributor model. Local distribution representation is a requirement for regulatory registration in most countries.
The model also provides significant benefits over a direct sales model, particularly for a company that is new to the IVD sector. It allows rapid access to the market via the distributor’s current customer base and using the distributor’s existing sales force. Besides existing customer networks, distributors come with a wealth of local market knowledge, such as an understanding of the regulatory requirements for marketing and advertising in-vitro diagnostic devices in their territories, importation and customs handling experience, and established logistics networks.
Expanding the distribution network, AnteoTech signed an additional six distributors during the quarter, and now has representation in Turkey, Greece, Romania, Philippines, Italy, Spain, and Portugal, bringing our distributor count to nine, covering 17 territories.
(20min delay)
